Crestwood Advisors Group LLC Takes Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Crestwood Advisors Group LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 16,200 shares of the company’s stock, valued at approximately $41,000.

Other institutional investors have also made changes to their positions in the company. State Street Corp increased its holdings in shares of ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after acquiring an additional 790,408 shares during the last quarter. Barclays PLC boosted its position in ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after purchasing an additional 202,248 shares during the period. Stephens Inc. AR acquired a new position in ImmunityBio during the 4th quarter valued at approximately $26,000. HighTower Advisors LLC acquired a new position in ImmunityBio during the 3rd quarter valued at approximately $136,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the period. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Stock Down 1.0 %

Shares of ImmunityBio stock opened at $3.00 on Thursday. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -3.26 and a beta of 0.94. The business has a fifty day simple moving average of $3.00 and a 200-day simple moving average of $3.76. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53.

Wall Street Analysts Forecast Growth

IBRX has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Friday, February 14th. BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target for the company.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.